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Table 1
Immune and Clinical Parameters
Standard group
(N¼23)
Study group
(N¼14)
Med (range) Median (range)
CD 34+ cells collected (x 10^6/kg) 11.7 (5.1 - 20.7) 13.0 (10.1 -28.0)
CD 34+ cells infused (x 10^6/kg) 5.0 (3.2 - 8.3) 9.7 (7.0 e 14.0)
Duration of ANC < 500 k/mL
(days)
4 (3 - 9) 4 (3 - 5)
Time to neutrophil engraftment
(days)
10 (8 - 14) 10 (9 - 11)
Duration of ALC< 500 k/mL (days) 14 (5 - 22) 14 (12 - 23)
Abstracts / Biol Blood Marrow Transplant 19 (2013) S178eS193S192existing bone marrow neuropathy may impair G-CSF driven
HSCmobilization and/or time to engrafment in the context of
ASCT for lymphoma. We retrospectively identiﬁed 46 ASCT
patients, all of whom were mobilized with G-CSF. Twenty
four patients were identiﬁed as poor mobilizers (PM) based
on the need for rescue pleriaxfor after mobilization failure,
while 22 patients were identiﬁed as good mobilizers (GM)
based on the ability to collect the target HSC dose within two
days of apheresis. We compared the clinical and immuno-
histochemical characteristics between the two groups. The
adequacy of bone marrow innervation was determined by
semiquantitative immunohistochemistical scoring of tyro-
sine hydroxylase positive (TH+) nerve terminals in pre-ASCT
bone marrow core biopsies. The mean TH scores were 2.33
for PM vs. 1.32 for GM (p¼0.2). There was a non signiﬁcant
trend towards a longer time to neutrophil/platelet engraft-
ment when no TH+ nerve terminals were identiﬁed vs. any
TH+ terminals identiﬁed (11/11.4 vs.10.8/10.7 days respec-
tively). HSC from the group with no TH+ nerve terminals had
less colony forming units (CFU) compared to the group that
had any TH+ terminals identiﬁed (7.1 vs. 10.4 x 106 CFU/kg, P
¼ .58). Also, the group with no TH+ nerve terminals had
lower peripheral blood CD34+ cell counts, before collection
and after G-CSF priming, compared to the group with any
TH+ terminals identiﬁed (18.3 vs. 28.7/mm3, P ¼ .66). As
expected, the time to neutrophil/platelet engrafment was
higher in the PM compared to the GM group (11.5/13.3 vs.
10.3/8.6, P ¼ .004/P < 0.0001, respectively). Owing to the
small sample size, we can't draw deﬁnite conclusions about
the impact of bone marrow neuropathy on HSC mobilization
and ASCT outcomes but we observed a trend toward higher
HSC mobilization, longer time to engraftment and decreased
HSC CFU capacity in patients with evidence of bone marrow
neuropathy. This is consistent with what other investigators
have demonstrated in animal models. Failure of G-CSF
mobilization was associated with longer time to neutrophil
and platelet engraftment in patients with lymphoma
undergoing ASCT.Time to lymphocyte engraftment
(days)
14 (9-21) 13 (11-22)
Time to PLT engraftment (days) 13 (0-17) 13.5 (10-20)
# of RBC Transfusions 0 (0 - 8) 0 (0 - 3)
# of PLT Transfusions 2 (0 - 12) 1 (1 - 4)
Days of T  38 deg C 1 (0-8) 0 (0-7)
Days on empiric/directed
antibiotics
5 (0 - 28) 0 (0 - 14)
Infections, N (%) 7 (30) 1 (7)
Days of diarrhea  500cc 0 (0-3) 0 (0-7)
Pts with ES, N (%) 0 (0) 3 (21)
Pts with infusion reactions, N (%) 2 (9) 0
Duration of hospitalization (days) 17 (13 - 36) 15 (13 - 19)157
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Background: High dose MEL with auto SCT is an established
therapeutic modality for MM. Although effective, it is associ-
ated with signiﬁcant symptom burden due to the obligate
periodofneutropeniaand increased riskof infection. Inanimal
models, infusing stemcells (SC) overa periodof days enhances
immune reconstitution (Felﬂy H, et al. 2009). Multiple SC
infusions could reduce the period of neutropenia and enhance
immune recovery resulting in a better tolerated procedure.
Methods: We are conducting a phase II trial of multiple
fractionated auto SC infusions after high-dose MEL. We
compared initial engraftment kinetics after high-doseMEL of
the ﬁrst 14 pts to receive multiple infusions (Days 0, +2, +4,+6) (study group) to 23 pts receiving the standard single SC
infusion (Day 0) (standard group). Pegﬁlgrastimwas given on
Day +1 and SCT was between October 2011 and July 2012 in
all pts.
Results: Table 1. Similar numbers of SCs were collected in
both groups. The number of SCs infused was 9.7 x 10^6
CD34+ cells/kg vs 5.0 x 10^6 CD34+ cells/kg in study and
standard pts. To date, the median duration of neutropenia
(days ANC < 500) and lymphopenia (days ALC < 500), and
days to neutrophil, lymphocyte and PLT engraftment were
similar. There were no signiﬁcant differences in the
number of red cell or PLT transfusions, days of fever,
diarrhea, empiric antibiotics or documented infections.
Despite multiple SC infusions, none of the pts in the study
group experienced infusion reaction. Engraftment
syndrome (ES) occurred in 3/14 of study pts. Duration of
hospitalization was 15 days in study pts vs 17 days in the
concurrent control group (P ¼ 0.01).
Conclusions:Multiple SC infusions after high doseMEL inpts
with MM were not associated with increased adverse effects
from DMSO or unexpected frequency of ES. Fractionating SCs
over a period of daysmay result in less antibiotic use, reduced
infection and was associated with shorter hospital stay. We
continue to collect pt reported symptom scores to determine
if we can improve pt experience during SCT.158
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